BrainCheck Used in Study Quantifying the Cognitive Effects of COVID-19

February 23, 2022 / Nueterra Capital Marketing

BrainCheck | A Nueterra Capital Portfolio Company


Researchers from The University of Texas at Austin and the University of California, San Francisco have conducted a study of cognitive outcomes in cases of non-critical, mild-to-moderate COVID-19. As explained in the published study in Frontiers in Psychology, the researchers used BrainCheck to test the subjects’ cognitive functioning. The research team noted that BrainCheck is FDA-approved, takes only 15 minutes to complete, is available in both English and Spanish, and “has been shown to have high sensitivity and specificity for mild or greater cognitive impairment.” The study was funded in part by the National Institutes of Health.

The cognitive healthcare platform developed by BrainCheck, a Nueterra Capital portfolio company, allows physicians to facilitate in-person or remote cognitive testing and is covered by Medicare and most insurers. A recent Series B funding round will allow BrainCheck to pursue new digital therapeutics for Alzheimer’s and related dementias.